Clinical Trial Update: A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD [Phase 3]

View source ↗

Summary

Phase 3 study evaluating how genetic and environmental factors affect response to Lucentis in wet age-related macular degeneration. The trial status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED